Owing to continuing high demand and use of capacity in the core segments, both Greiner Bio-One and its suppliers invested significant sums in the enlargement of global production. The bulk of an investment volume of EUR 44.8 million flowed into new production facilities for existing core products. It also represents a platform for further expansion in the core area of blood collection.
In addition, the storage space available in Frickenhausen (Germany) was more than doubled. After a construction period of only a year, a new, fully automated high-bay warehouse fitted with the latest storage technology was put into operation thereby replacing the facility used to date. The warehouse is part of an extensive infrastructure project that forms the basis for greater efficiency in the material supply and logistics areas, and will be concluded in 2019 with an increase in production capacity.
Focus on further growth In spite of diffcult market circumstances, currency effects and stagnation with regard to individual key accounts and major orders, business volume achieved the level of the preceding year and profitability maintained at an excellent level – the turnover amounted to 473 million euros In particular, solid growth was achieved in the safety products area and the company gained ground in the regional markets in Southern and Eastern Europe, and South America. However, rising material and raw material prices as well as higher freight costs all served to hinder an even better business development.
“We are preparing for further growth through a significant increase in our production capacities”, Rainer Perneker, CEO Greiner Bio-One International GmbH.
The Asian region is one of Greiner Bio-One’s most important growth markets and for example, in China the company has been able to establish a solid position in the preanalytics field within the Beijing area. In October, a second major step followed with the foundation of an additional branch in Shanghai staffed by a focused and specialized team. The joint aim is to step up efforts in the biosciences market and move closer to the customers in this business segment.
The complete annual report can be found at www.greiner.com
Greiner Bio-One International GmbH
Greiner Bio-One specialises in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into three divisions – Preanalytics, BioScience and Sterilisation. As an Original Equipment Manufacturer (OEM), Greiner Bio-One provides individual solutions in the area of custom-made design developments and production processes for the life sciences and medical sectors. In 2018, Greiner Bio-One International GmbH generated a turnover of 473 million euros and had over 2,300 employees, 27 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner AG, which is based in Kremsmünster (Austria).
